21 Results
Sort By:
Published on December 4, 2024
Clinical-stage drug developer Terns Pharmaceuticals on Tuesday announced promising data from its Phase I clinical study evaluating its small molecule allosteric BCR-ABL inhibitor drug candidate TERN-701 in patients with relapsed/refractory chronic myeloid leukemia (CML). The CARDINAL trial’s data from 15 patients exhibited both safety and efficacy at all four dosing…
Published on September 21, 2020
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. About 15% of leukemias in adults are CML. Tyrosine kinase inhibitors (TKI) have helped transformed the prognosis of the disease with…
Published on April 4, 2018
Sponsor: Download this eBook to learn how MolecularMD helped usher in a new era of CML treatment now prescribed by progressive clinicians. Get the eBook
Published on September 24, 2024
Researchers have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment significantly increases the number of patients with chronic-phase chronic myeloid leukemia (CP-CML) who achieved deep molecular responses, potentially allowing them to discontinue treatment. “Treatment free remission has become a common therapeutic goal for patients with CP-CML, said…
Published on February 9, 2024
Researchers from the University of Illinois Chicago (UIC) in collaboration with other institutions have shed light on why the anti-leukemia drug ponatinib harms the heart and propose a possible solution. Chronic myeloid leukemia (CML) patients, for whom other treatments have failed, often turn to ponatinib—a tyrosine kinase inhibitor binding the…
Published on April 10, 2023
Sponsored content brought to you by When it comes to developing new cancer therapeutics, time is of the essence—for the patients that need treatments most, every day counts. Traditional benchmarks for evaluating a treatment’s effectiveness in clinical trials, such as five-year survival rates, deliver prognostic insights on a slower timeline…
Published on October 26, 2022
A potential therapeutic target for triple negative breast cancer (TNBC) has been pinpointed by researchers at Virginian Commonwealth University (VCU) Massey Cancer Center. Importantly, this target may be effective in black patients, who suffer disproportionally from the disease. Further, the researchers may have a lead on a biomarker—c-MYC—to guide treatment.…
Published on October 7, 2022
Precision medicine company Tempus announced on Thursday that it will collaborate with Kartos Therapeutics to develop a companion diagnostic (CDx) to be used in the biopharma company’s ongoing Phase II clinical trial of navtemadlin (KRT-232), to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible…
Published on May 20, 2021
An ongoing study shows that combining ponatinib and blinatumomab provides remarkable complete responses in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Both are usually treated with tyrosine kinase inhibitors (TKI) and systemic chemotherapy, often with the addition of an…
Published on October 4, 2019
Cepheid announced that it has received clearance from the FDA for its Xpert BCR-ABL Ultra for monitoring disease burden in patients with chronic myeloid leukemia (CML). An important aspects of managing CML is regular and frequent monitoring of a patient’s response to therapy by measuring BCR-ABL gene transcript levels as…
Published on February 26, 2019
The FDA, Centers for Disease Control and Prevention (CDC), and the Centers for Medicare and Medicaid Services (CMS) said today they have formed a task force designed to help facilitate rapid development and deployment of diagnostic tests in clinical and public health laboratories during public health emergencies. The Tri-Agency Task…
Published on February 21, 2019
Pharmaceutical, biotech, and medical device contract research organization (CRO) ICON, based in Dublin, Ireland announced in its year-end earnings statement that it has acquired molecular diagnostics and research laboratory company MolecularMD. The deal, whose terms were not disclosed, provides ICON with significant reach into the area of precision medicine research…
Published on November 29, 2018
Sysmex and MolecularMD will partner to develop and commercialize companion diagnostics for precision medicines through a master collaboration agreement whose value was not disclosed. Under their non-exclusive agreement, the companies said, they aim to align and accelerate commercialization of companion diagnostics with therapeutic drug commercialization, as well as leverage the…
Published on October 23, 2018
NeoGenomics Laboratories said today it has agreed to acquire the clinical oncology laboratory Genoptix for about $140 million cash and stock combined, in a deal designed to expand the buyer’s presence in cancer testing. With headquarters and labs in Carlsbad, CA, Genoptix is a provider of personalized and comprehensive diagnostic…
Published on June 4, 2018
MolecularMD announced it has entered an exclusive agreement with clinical oncology laboratory Genoptix to market and perform the testing services for the MRDx BCR-ABL test, a companion diagnostic that identifies Ph+CML patients in the chronic phase taking Tasigna who are eligible for initiation and monitoring of treatment-free remission (TFR). TFR…